查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829674

2025年全球藥物釋放型支架市場報告

Drug Eluting Stent Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，藥物釋放型支架市場呈現強勁成長勢頭，市場規模從2024年的76.3億美元增至2025年的82.6億美元，複合年成長率達8.3%。在過去一段時間內，治療方案的改進、臨床證據的累積、監管部門的核准、醫療經濟效益以及對指南和建議的需求推動了市場的成長。

預計未來幾年藥物釋放型支架市場規模將強勁成長，到2029年將達到110.7億美元，複合年成長率為7.6%。預測期內的成長可歸因於人口老化和慢性病負擔、適應症擴大、醫療保健報銷政策、全球市場擴張以及以患者為中心的醫療等因素。預測期內的主要趨勢包括個人化醫療、微創技術、新興醫療技術和下一代藥物製劑。

藥物釋放型支架 (DES) 是醫療設備。 DES 是一種小型網狀管，通常由金屬製成，在經經皮冠狀動脈介入治療 (PCI) 或血管成形術中插入狹窄或阻塞的冠狀動脈。

藥物釋放型支架主要分為聚合物基和非聚合物基兩種。聚合物基藥物釋放型支架 (DES) 是一種塗覆薄聚合物層的支架，此層包覆藥物，以便輸送至動脈壁。這些藥物包括Sirolimus、紫杉醇、佐他莫司、Everolimus和比奧莫司，並可採用鈷鉻合金、鉑鉻合金、鎳鈦合金和可生物分解材料等支架。它們被醫院和專科診所等終端用戶用於治療冠狀動脈疾病和周邊血管疾病。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要醫療設備重新認證，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供藥物釋放型支架市場統計數據，包括全球藥物釋放型藥物釋放型支架行業規模、各地區市場佔有率、競爭對手的市場佔有率、詳細的藥物釋放型藥物釋放型細分市場、市場趨勢和商機，以及您在藥物釋放型支架市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的全方位觀點。

未來五年7.6%的預測成長率，較我們先前對該市場的預測略有下降0.6%。下降的主要原因是美國與其他國家之間關稅的影響。美國可能會直接感受到這種影響，因為來自比利時和新加坡等主要地區的可生物分解聚合物載體和鈷鉻合金平台的供應鏈中斷，這可能導致冠狀動脈介入治療的延誤和救命心臟設備價格的上漲。此外，這種影響可能會透過互惠關稅以及不斷升級的貿易緊張局勢和限制對全球經濟和貿易的負面影響，在更廣泛的範圍內顯現。

預計未來幾年，日益嚴重的水污染水平將推動生態毒性檢測市場的成長。水污染是指河流、湖泊、海洋和地下水等水體受到有害污染物的污染，對人類健康、水生生物和環境造成不利影響。污染加劇的因素包括工業廢水、含有化學肥料和農藥的農業徑流、不當的廢棄物處理、導致污水污染的都市化以及石油洩漏等。生態毒理學研究評估化學物質和重金屬等污染物對水生生物的毒性，並有助於制定污染防治策略，以減輕水污染的有害影響。例如，根據白金漢期貨2024年8月發布的數據，預計2022年英格蘭河流和海洋的污水排放小時數將達到175萬小時，2023年將增加至360萬小時。因此，日益嚴重的水污染正在推動生態毒理學研究的需求。

藥物釋放型支架市場的公司正專注於開發創新的輸送系統，例如雙層球囊，以改善患者預後並推動介入性心臟病學的發展。藥物釋放型支架系統中的雙層球囊能使藥物均勻且可控地作用於動脈壁，進而提高藥物輸送和支架置入的精準度。例如，美敦力公司於2022年8月宣布推出其最新一代藥物釋放型冠狀動脈支架系統Onyx Frontier，旨在增強輸送系統，並藉鑒上一代Resolute Onyx DES的急性性能和臨床數據。 Onyx Frontier DES採用與Resolute Onyx相同的高品質支架平台，尺寸範圍廣泛，能夠使用直徑從2.0毫米到5.0毫米不等的支架治療患者。顯著的設計改進，包括創新的雙層球囊、減少的橫截面積和增加的導管靈活性，與上一代 Resolute Onyx DES 相比，輸送能力提高了 16%，同時保持了徑向強度。

2023年10月，Cordis收購了MedAlliance，具體金額未揭露。此次收購旨在進一步發揚Cordis在心血管領域的創新傳統，並擴大產品系列。 MedAlliance是一家總部位於瑞士的醫療設備製造商和分銷商，專注於藥物釋放型支架。

藥物釋放型支架市場由提供術前評估、手術介入、術中監測、術後照護和病患教育等服務的營業單位獲得的收益所構成。市場價值還包括服務供應商銷售或包含在其服務產品中的相關商品的價值。藥物釋放型支架市場還包括導管導引線、血管成形術裝置、血管內影像系統、止血裝置和診斷工具等產品的銷售。此市場價值為“出廠價”，即商品製造商或生產商銷售給其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接銷售給最終客戶的商品價值。該市場中的商品價值還包括商品製造商銷售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球藥物釋放型支架：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球藥物釋放型支架市場：成長率分析
  • 全球藥物釋放型支架市場表現：規模與成長，2019-2024
  • 全球藥物釋放型支架市場預測：規模與成長，2024-2029年，2034年
  • 全球藥物釋放型支架：總目標市場（TAM）

第6章 市場細分

  • 全球藥物釋放型支架市場（按產品、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 聚合物基
  • 不含聚合物
  • 全球藥物釋放型支架市場：依藥物類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • Sirolimus
  • 紫杉醇
  • 佐他莫司
  • Everolimus
  • 百奧利莫斯
  • 其他藥物
  • 全球藥物釋放型支架市場（按支架類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 鈷鉻合金
  • 鉑鉻
  • 鎳鈦合金
  • 可生物分解
  • 其他支架
  • 全球藥物釋放型支架市場應用、效能及預測（2019-2024、2024-2029、2034）
  • 冠狀動脈疾病
  • 周圍血管疾病
  • 全球藥物釋放型支架市場（按最終用戶、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 專科診所
  • 全球藥物釋放型支架市場：按聚合物基底、類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 耐用聚合物藥物釋放型支架
  • 可生物分解聚合物藥物釋放型支架
  • 全球藥物釋放型支架市場：按無聚合物、類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 藥物塗層裸金屬支架
  • 其他無聚合物藥物釋放型支架

第7章 區域和國家分析

  • 全球藥物釋放型支架市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球藥物釋放型支架市場：依國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 藥物釋放型支架市場：競爭格局
  • 藥物釋放型支架市場：公司簡介
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Terumo Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • InspireMD Inc.
  • B. Braun Melsungen AG
  • Cook Group Incorporated
  • Lepu Medical Technology（Beijing）Co. Ltd.
  • Biotronik
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Biosensors International Group Ltd.
  • OrbusNeich Medical Company Limited
  • Alvimedica Medical Technologies
  • Hexacath
  • Elixir Medical Corporation
  • Translumina GmbH
  • Cardionovum GmbH
  • QualiMed Innovative Medizinprodukte GmbH

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年藥物釋放型支架市場：提供新機會的國家
  • 2029年藥物釋放型支架市場：細分市場帶來新機會
  • 2029年藥物釋放型支架市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r30041u

A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.

The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The drug eluting stent market research report is one of a series of new reports from The Business Research Company that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug eluting stent market size has grown strongly in recent years. It will grow from $7.63 billion in 2024 to $8.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the need for improved treatment options, clinical evidence, regulatory approval, healthcare economics, and guidelines and recommendations.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to an aging population and chronic disease burden, the expansion of indications, healthcare reimbursement policies, global market expansion, and patient-centered care. Major trends in the forecast period include personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.

The forecast of 7.6% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for biodegradable polymer carriers and cobalt-chromium platforms, sourced from key regions such as Belgium and Singapore, which could lead to delayed coronary interventions and increased prices for life-saving cardiac devices.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising levels of water pollution are expected to drive the growth of the ecotoxicological studies market in the coming years. Water pollution refers to the contamination of water bodies, such as rivers, lakes, oceans, and groundwater, by harmful pollutants, which negatively impact human health, aquatic life, and the environment. The increasing pollution is driven by factors like industrial discharges, agricultural runoff containing fertilizers and pesticides, improper waste disposal, urbanization causing sewage contamination, and oil spills. Ecotoxicological studies assess the toxicity of pollutants, such as chemicals, heavy metals, and other contaminants, on aquatic organisms, helping to develop pollution control strategies to reduce the harmful effects of water pollution. For example, data from Buckingham Futures in August 2024 reported that sewage spills in England's rivers and seas totaled 1.75 million hours in 2022, which increased to 3.6 million hours in 2023. As a result, the growing water pollution is fueling the demand for ecotoxicological studies.

Companies operating in the drug-eluting stent market are directing their efforts toward developing innovative delivery systems, such as the dual-layer balloon, to enhance patient outcomes and advance interventional cardiology. A dual-layer balloon within a drug-eluting stent system improves precision in drug delivery and stent deployment by offering better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc introduced Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems, building upon the acute performance and clinical data from the previous Resolute Onyx DES generation. The Onyx Frontier DES utilizes the same high-quality stent platform as Resolute Onyx and features a wide size range to treat patients with diameters ranging from 2.0mm to 5.0mm. Notable design enhancements include a groundbreaking dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility, resulting in a 16% increase in deliverability compared to the previous Resolute Onyx DES generation, while maintaining radial strength.

In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Eluting Stent Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug eluting stent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug eluting stent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug eluting stent market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Polymer-Based; Polymer-Free
  • 2) By Drug: Sirolimus; Paclitaxel; Zotarolimus; Everolimus; Biolimus; Other Drugs
  • 3) By Scaffold: Cobalt-Chromium; Platinum-Chromium; Nitinol; Biodegradable; Other Scaffolds
  • 4) By Application: Coronary Diseases; Peripheral Vascular Diseases
  • 5) By End-User: Hospitals; Specialty Clinic
  • Subsegments:
  • 1) By Polymer-Based: Durable Polymer Drug-Eluting Stents; Biodegradable Polymer Drug-Eluting Stents
  • 2) By Polymer-Free: Bare-Metal Stents With Drug Coating; Other Polymer-Free Drug-Eluting Stents
  • Companies Mentioned: Johnson & Johnson Services Inc.; Abbott; Medtronic plc; Boston Scientific Corporation; Terumo Corporation; InspireMD Inc.; B. Braun Melsungen AG; Cook Group Incorporated; Lepu Medical Technology (Beijing) Co. Ltd.; Biotronik; Meril Life Sciences Pvt. Ltd.; MicroPort Scientific Corporation; Biosensors International Group Ltd.; OrbusNeich Medical Company Limited; Alvimedica Medical Technologies; Hexacath; Elixir Medical Corporation; Translumina GmbH; Cardionovum GmbH; QualiMed Innovative Medizinprodukte GmbH; InSitu Technologies Inc.; Acrostak AG; SINOMED Innovation Inc.; Svelte Medical Systems Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drug Eluting Stent Market Characteristics

3. Drug Eluting Stent Market Trends And Strategies

4. Drug Eluting Stent Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Drug Eluting Stent Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Drug Eluting Stent PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Drug Eluting Stent Market Growth Rate Analysis
  • 5.4. Global Drug Eluting Stent Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Drug Eluting Stent Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Drug Eluting Stent Total Addressable Market (TAM)

6. Drug Eluting Stent Market Segmentation

  • 6.1. Global Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymer-Based
  • Polymer-Free
  • 6.2. Global Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sirolimus
  • Paclitaxel
  • Zotarolimus
  • Everolimus
  • Biolimus
  • Other Drugs
  • 6.3. Global Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cobalt-Chromium
  • Platinum-Chromium
  • Nitinol
  • Biodegradable
  • Other Scaffolds
  • 6.4. Global Drug Eluting Stent Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Coronary Diseases
  • Peripheral Vascular Diseases
  • 6.5. Global Drug Eluting Stent Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinic
  • 6.6. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Based, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Durable Polymer Drug-Eluting Stents
  • Biodegradable Polymer Drug-Eluting Stents
  • 6.7. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Free, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bare-Metal Stents With Drug Coating
  • Other Polymer-Free Drug-Eluting Stents

7. Drug Eluting Stent Market Regional And Country Analysis

  • 7.1. Global Drug Eluting Stent Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Drug Eluting Stent Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drug Eluting Stent Market

  • 8.1. Asia-Pacific Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drug Eluting Stent Market

  • 9.1. China Drug Eluting Stent Market Overview
  • 9.2. China Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drug Eluting Stent Market

  • 10.1. India Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drug Eluting Stent Market

  • 11.1. Japan Drug Eluting Stent Market Overview
  • 11.2. Japan Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drug Eluting Stent Market

  • 12.1. Australia Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drug Eluting Stent Market

  • 13.1. Indonesia Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drug Eluting Stent Market

  • 14.1. South Korea Drug Eluting Stent Market Overview
  • 14.2. South Korea Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drug Eluting Stent Market

  • 15.1. Western Europe Drug Eluting Stent Market Overview
  • 15.2. Western Europe Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drug Eluting Stent Market

  • 16.1. UK Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drug Eluting Stent Market

  • 17.1. Germany Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drug Eluting Stent Market

  • 18.1. France Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drug Eluting Stent Market

  • 19.1. Italy Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drug Eluting Stent Market

  • 20.1. Spain Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drug Eluting Stent Market

  • 21.1. Eastern Europe Drug Eluting Stent Market Overview
  • 21.2. Eastern Europe Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drug Eluting Stent Market

  • 22.1. Russia Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drug Eluting Stent Market

  • 23.1. North America Drug Eluting Stent Market Overview
  • 23.2. North America Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drug Eluting Stent Market

  • 24.1. USA Drug Eluting Stent Market Overview
  • 24.2. USA Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drug Eluting Stent Market

  • 25.1. Canada Drug Eluting Stent Market Overview
  • 25.2. Canada Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drug Eluting Stent Market

  • 26.1. South America Drug Eluting Stent Market Overview
  • 26.2. South America Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drug Eluting Stent Market

  • 27.1. Brazil Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drug Eluting Stent Market

  • 28.1. Middle East Drug Eluting Stent Market Overview
  • 28.2. Middle East Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drug Eluting Stent Market

  • 29.1. Africa Drug Eluting Stent Market Overview
  • 29.2. Africa Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drug Eluting Stent Market Competitive Landscape And Company Profiles

  • 30.1. Drug Eluting Stent Market Competitive Landscape
  • 30.2. Drug Eluting Stent Market Company Profiles
    • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbott Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Terumo Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Drug Eluting Stent Market Other Major And Innovative Companies

  • 31.1. InspireMD Inc.
  • 31.2. B. Braun Melsungen AG
  • 31.3. Cook Group Incorporated
  • 31.4. Lepu Medical Technology (Beijing) Co. Ltd.
  • 31.5. Biotronik
  • 31.6. Meril Life Sciences Pvt. Ltd.
  • 31.7. MicroPort Scientific Corporation
  • 31.8. Biosensors International Group Ltd.
  • 31.9. OrbusNeich Medical Company Limited
  • 31.10. Alvimedica Medical Technologies
  • 31.11. Hexacath
  • 31.12. Elixir Medical Corporation
  • 31.13. Translumina GmbH
  • 31.14. Cardionovum GmbH
  • 31.15. QualiMed Innovative Medizinprodukte GmbH

32. Global Drug Eluting Stent Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Eluting Stent Market

34. Recent Developments In The Drug Eluting Stent Market

35. Drug Eluting Stent Market High Potential Countries, Segments and Strategies

  • 35.1 Drug Eluting Stent Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Drug Eluting Stent Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Drug Eluting Stent Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer